Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	1/22/2018 3:18:14 PM
	Read Replies (1) of 1840

Pair that can mach CART-candidates efficacy (without compromising safety) may be bispecific (CD3-X)/PD1l(L1) combination??? In 2015 AMGN/MRK formed first trial collaboration for Blyncito/Keytruda (<THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen's CD19 bispecific T cell engager (BiTE®), and KEYTRUDA is Merck's anti-PD-1 therapy. The study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.>). So far next to nothing ( clinicaltrials.gov )??? Is anyone keeping track on those or similar combination that had show significant progress?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next